{"ok":true,"nota":{"id":"e2750e9d2f42906d","slug":"un-test-de-infeccion-reciente-podria-acortar-y-abaratar-las-pruebas-de-e2750e","titulo":"Un test de infección reciente podría acortar y abaratar las pruebas de vacunas contra la tuberculosis","resumen":"Investigadores simularon cómo cambiaría el tamaño de los ensayos de vacunas contra la tuberculosis si se seleccionaran participantes con infección reciente. Compararon cuántas personas harían falta en cada escenario para llegar a conclusiones válidas.","fuente":"medrxiv","fuenteNombre":"medRxiv · preprints","color":"#1f7a4d","autor":"Hadley, L., Brown, T. S., Nelson, K., Kissler, S. M.","url":"https://www.medrxiv.org/content/10.64898/2026.10.19.26365122v1?rss=1","imagen":"/hoy/portada/e2750e9d2f42906d","tema":"salud","subtemas":["tuberculosis","vacunas","ensayos clínicos","diagnóstico de infección","salud pública"],"entidades":["Mycobacterium tuberculosis"],"formato":"dato","entretenimiento":false,"pubTs":"2026-10-21T00:00:00.000Z","indexTs":"2026-10-22T04:37:56.220Z","hash":"debb5a748cb60c5f17ad64af501d1a5b668b397b305d697104ad191e8d3c56d4","tsa":{"time":"Oct 22 04:38:37 2026 GMT","provider":"freetsa.org","sobre":"sello"},"stats":{"views":0,"likes":0,"clicks":0,"dwell":0},"tipo":"normal","registro":"hallazgo","porQueImporta":"Hoy una vacuna contra la tuberculosis necesita miles de voluntarios y años de seguimiento, porque la mayoría de quienes tienen la bacteria nunca enferma. Si se pudiera filtrar a quienes se infectaron hace poco, los ensayos serían más chicos y rápidos. Para la Argentina, que tiene tuberculosis en varias provincias, eso podría acelerar la llegada de una vacuna mejor que la actual. Aun así, la mejora depende de que el test funcione bien, algo que todavía no está validado.","quienFirma":"medRxiv (preprint; institución principal no indicada en la fuente)","confianza":"preprint","consulta":null},"sello":{"hash":"debb5a748cb60c5f17ad64af501d1a5b668b397b305d697104ad191e8d3c56d4","sello":"19922cd129aebf69b202c1c955dfe536e6479de5030f83bac8419fa0de6e0bb7","beacon":{"drand":{"cadena":"8990e7a9aaed2ffed73dbd7092123d6f289930540d7651336225dc172e51b2ce","ronda":6573763,"aleatorio":"ac1ab9766ef209323093f9521e7402b29370fa8f04af200361451518fae9c9b2","tiempo":"2026-10-22T04:38:30.000Z"},"nist":{"cadena":2,"pulso":1994087,"salida":"2CAE0B0247F8B2C1365D5848B4971A88B86F8096596AB659C9B46851CC37B71B43230BE62392778D57CA4D0DAE3440419DC67D4E27A84A89E3AA5B314736F2A3","tiempo":"2026-10-22T04:38:00.000Z"},"noAntes":"2026-10-22T04:38:30.000Z"},"verificacion":{"drand":true,"nist":true},"tsa":{"time":"Oct 22 04:38:37 2026 GMT","provider":"freetsa.org","sobre":"sello"},"original":{"titulo":"Can identifying recent Mycobacterium tuberculosis infection support faster tuberculosis vaccine trials?","descripcion":"Background: TB vaccine development is hampered by the natural history of M. tuberculosis: most infected people rarely progress to disease, so trials must be very large and long to accrue sufficient disease endpoints. Current trials enrol IGRA-positive participants (IGRA: Interferon-Gamma Release Assays), but IGRAs remain positive for many years and cannot distinguish recent from remote infection. Tests for recent infection are now in development, and we argue they could make trials substantially more efficient. Here, we investigate how screening participants prior to enrolment with a test for recent M.tb infection could impact the total number of enrollees required for an adequately-powered ","pubDate":"2026-10-21","url":"https://www.medrxiv.org/content/10.64898/2026.10.19.26365122v1?rss=1"},"indexado":"2026-10-22T04:37:56.220Z"}}